FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
CIPLA
952.7
-7.45 (-0.78%)
Updated 10:24 22/06 IST
CIPLA Buy or Sell - FrontPage Forums
23 Users have submitted 25 trade ideas of Rs. 3,146,470.91 for CIPLA
Disclaimer88% Bullish
12% Bearish
CIPLA Buy or Sell - Brokerage Reports
No. of reports in last year
8
No. of analysts
3
Average Consensus Forecast
874.75
Consensus Potential
-11.37%
CIPLA Ratings
Long term CIPLA rating by FrontPage users
- ★★
- ★★
- ★★
- ★★
- ★★
3.6/5 (5 Ratings)
Find answers to all your questions on live CIPLA message board: Is CIPLA buy or sell? Should I buy CIPLA shares? Why are CIPLA shares falling? Should I invest in CIPLA stock?
- Home
- CIPLA Forum
CIPLA Share Price Discussion
C
Reputation: 4,928 • Yesterday 2:41 AM
Very gd morning..namaskar adaab...🙏
🙏INTRADAY Stocks commodities and index TREND LEVELS BASED ON ALGO TRADE...🙏
Date: 21st June 2021
Time: 9:10am
Trend:
"NIFTY21JUNFUT LEVELS - Buy at 15646.11 with Target of 15908.51/16020.4 , Add one lot 15611.55 ,Sell at 15576.99 wit...
Read more...
Like
Reply
T
Reputation: 1,656 • Jun 20 12:46 PM
BUY CIPLA ABOVE 968
SUPPORT - 949 CLBS
TGT - 988 998 1010 ++
Like
Reply (2)
See all replies
Can take option
SIR WITHOUT KNOWLEDGE DONT BUY MESSAGE ME WHATAPP
M
Reputation: 69 • Jun 20 6:44 AM
#CIPLA FUTURE CHART.......ABOVE 966.......GOOD UP MOVE IN THIS COUNTER🎯
Like
Reply
I
Reputation: 120 • Jun 19 6:06 AM
#CIPLA Daily Chart
1. you can see 1000+ level in next week sl will be 940
2. cup and handle pattern breakout now its come for retesting
3. full market is down but pharma sector can again shine due to third wave of covid 19
Like
Reply
N
Reputation: 14,612 • Jun 19 4:11 AM
Cipla to tap foreign cos for large-scale vax play
Moving beyond a wide portfolio of Covid drugs and diagnostic kits, the Mumbai-based company — with revenues of nearly Rs 20,000 crore — now plans to partner foreign companies for large-scale fill-and-finish services for coronavirus vaccines.
Moving beyond a wide portfolio of Covid drugs and diagnostic kits, the Mumbai-based company — with revenues of nearly Rs 20,000 crore — now plans to partner foreign companies for large-scale fill-and-finish services for coronavirus vaccines.
The Economic Times
Like
Reply
K
Reputation: 5,569 • Jun 19 11:23 AM
==============================
4
Reply (2)
See all replies
Is it good time to enter in Glenmark, Pizer?
@krishk last leg of the rally in Pharma is pending!
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 2,00,000 Indian traders and discuss trades, strategies, news & views on any stock.
- keyboard_arrow_down
CIPLA Share Price - Technicals
- NewsBotJun 19 4:11 AMCipla to tap foreign cos for large-scale vax playThe Economic TimesNewsBotJun 17 1:51 AM
Bombay HC asks Maharashtra government to find out how Sonu Sood and MLA Zeeshan Siddique procured anti-Covid drugsThe Economic TimesNewsBotJun 1 10:51 AM
COVID-19: Antibody cocktail treatment begins at Delhi's Sir Ganga Ram HospitalThe Economic TimesNewsBotMay 31 3:26 AM
Close to commit over $1-bn to Moderna for COVID-19 booster vaccine; Provide price capping waiver, indemnity: Cipla to GovtThe Economic TimesNewsBotMay 30 3:11 AM
72-year-old Covid patient given 'antibody cocktail' at Fortis in MohaliThe Economic TimesNewsBotMay 27 3:31 AM
India's Zydus Cadila seeks human trial approval for COVID-19 antibody cocktailThe Economic TimesNewsBotMay 24 7:26 AM
Cipla to market Roche's Antibody Cocktail in IndiaThe Economic TimesNewsBotMay 20 4:36 AM
Cipla launches RT-PCR test kit 'ViraGen' in India partnership with Ubio BiotechThe Economic TimesNewsBotMay 18 7:31 AM
Core portfolio of Cipla very strong, momentum intact: Umang VohraThe Economic TimesNewsBotMay 17 4:41 AM
Remdesivir production capacity increased to around 1.19 cr crore vials a month: GovtThe Economic Times
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.